A Phase 3 interventional study of Tirzepatide and Risedronate in Obesity, sponsored by Wake Forest University Health Sciences. Not yet recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Wake Forest University Health Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Obesity by Wake Forest University Health Sciences — 4 open to participants now, 5 under way, 2 of them phase 3. Obesity · Wake Forest University Health Sciences.
Among the 46 studies in Obesity by Wake Forest University Health Sciences, this one is the 19th largest by planned enrollment of the 40 interventional ones that give a count, is the only one that started in 2027, is one of 2 in phase 3, and was the 46th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →4 of the 46 studies in Obesity by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 45–75
Wake Forest University Health Sciences · Sites in United States
Ages 18+ · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 18–39 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 88 across the 40 interventional studies, 87 across the 6 observational. Of the 40 that completed or were terminated, 16 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 202 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
2 of the studies in Obesity by Wake Forest University Health Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05674799Wake Forest University Health SciencesNDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks | 2027-05-31 |
| NCT06861439Wake Forest University Health SciencesGLP-1s to Enhance Lasting Optimal Weight | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies in Obesity by Wake Forest University Health Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tirzepatide produces rapid, clinically meaningful weight loss. In older adults, however, substantial weight reduction may accelerate loss of bone and muscle, increase frailty risk, and compound age-related skeletal vulnerability. The purpose of this study is to find out if taking risedronate along with tirzepatide preserves musculoskeletal health during tirzepatide-associated weight loss.
Tirzepatide produces rapid, clinically meaningful weight loss. Weight loss of this magnitude is accompanied by increased bone turnover, hip bone loss, and loss of fat-free mass. Risedronate is a bisphosphonate therapy that inhibits osteoclast-mediated bone resorption and has an established monthly oral regimen. Pilot bariatric-surgery data from the investigative team support feasibility [1], attenuation of bone loss and resorption [2], and a signal for preservation of appendicular lean mass [3]. This single-center, 12-month, randomized, double-blind, placebo-controlled, parallel-group phase 3 clinical trial evaluates the premise that risedronate will blunt the skeletal consequences of tirzepatide-associated weight loss and may secondarily preserve muscle through bone-muscle signaling pathways.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tirzepatide · Drug: Risedronate
Drug: Tirzepatide · Other: Placebo
Tirzepatide 2.5 mg weekly for 4 weeks, then 5 mg, 7.5 mg, and 10 mg at 4-week intervals as tolerated; continue 10 mg weekly through month 12.
Risedronate 150 mg orally once monthly for 12 doses
risedronate matching placebo orally once monthly for 12 doses
Change in Hip Bone Mineral Density
change in total hip areal bone mineral density by DXA
Time frame: from baseline to month 12
Appendicular Lean Mass
appendicular lean mass by DXA
Time frame: Month 6, Month 12
Hip Bone Strength
hip bone strength by QCT-derived finite element analysis
Time frame: Month 6, Month 12
Distal Tibia Trabecular Number
distal tibia trabecular number by HR-pQCT
Time frame: Month 6, Month 12
Gait Speed
fast-paced gait speed from the 400-m walk test
Time frame: Month 6, Month 12
Start is estimated for Jun 2027; primary completion for Nov 2031, 53 months later.
Of 63 non-industry phase 3 interventional studies under Obesity, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 56. This study's planned 53 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →